Literature DB >> 35476619

The Invisible Hand of Industry.

X Mona Guo1, Emma L Barber2,3,4.   

Abstract

Over the last decades, federal funding for medical research has decreased, while industry funding has increased. The majority of clinical trials are now industry funded. Involvement of industry raises documented concerns of reporting and publication bias, data suppression, and conclusions that may more favorably align with funder motivations rather than study results. However, industry involvement may also lead to scientific innovation, efficiency, and a more rapid timeline to bring new developments to patients. Through a careful review of a manuscript, the reader can understand the nature of industry involvement and interpret the results in this context.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2022        PMID: 35476619      PMCID: PMC9060382          DOI: 10.1097/GRF.0000000000000697

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   1.966


  44 in total

1.  MSJAMA: Industry funding of clinical trials: benefit or bias?

Authors:  Sameer S Chopra
Journal:  JAMA       Date:  2003-07-02       Impact factor: 56.272

2.  Conflicts-of-interest disclosures at the 2010 AUGS Scientific Meeting.

Authors:  Olga Ramm; Linda Brubaker
Journal:  Female Pelvic Med Reconstr Surg       Date:  2012 Mar-Apr       Impact factor: 2.091

Review 3.  Ghost- and guest-authored pharmaceutical industry-sponsored studies: abuse of academic integrity, the peer review system, and public trust.

Authors:  Dennis K Flaherty
Journal:  Ann Pharmacother       Date:  2013-06-26       Impact factor: 3.154

4.  Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study.

Authors:  Nicholas J DeVito; Seb Bacon; Ben Goldacre
Journal:  Lancet       Date:  2020-01-17       Impact factor: 79.321

5.  Patients' views on financial conflicts of interest in cancer research trials.

Authors:  Lindsay A Hampson; Manish Agrawal; Steven Joffe; Cary P Gross; Joel Verter; Ezekiel J Emanuel
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

Review 6.  Impact of industry collaboration on randomised controlled trials in oncology.

Authors:  Anne Linker; Annie Yang; Nitin Roper; Evans Whitaker; Deborah Korenstein
Journal:  Eur J Cancer       Date:  2016-12-24       Impact factor: 9.162

7.  Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

Authors:  Kathleen Moore; Nicoletta Colombo; Giovanni Scambia; Byoung-Gie Kim; Ana Oaknin; Michael Friedlander; Alla Lisyanskaya; Anne Floquet; Alexandra Leary; Gabe S Sonke; Charlie Gourley; Susana Banerjee; Amit Oza; Antonio González-Martín; Carol Aghajanian; William Bradley; Cara Mathews; Joyce Liu; Elizabeth S Lowe; Ralph Bloomfield; Paul DiSilvestro
Journal:  N Engl J Med       Date:  2018-10-21       Impact factor: 91.245

8.  Investigator initiated trials (IITs).

Authors:  Viraj Suvarna
Journal:  Perspect Clin Res       Date:  2012-10

Review 9.  Conflict of interest in clinical practice guideline development: a systematic review.

Authors:  Susan L Norris; Haley K Holmer; Lauren A Ogden; Brittany U Burda
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

10.  Differences in the volume of pharmaceutical advertisements between print general medical journals.

Authors:  Jennifer Gettings; Braden O'Neill; Dave A Chokshi; James A Colbert; Peter Gill; Gerald Lebovic; Joel Lexchin; Navindra Persaud
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.